For U.S.-based small and mid-sized biopharma companies, Australia offers a strategically attractive destination for early clinical development. It combines rapid study start-up, substantial cost savings, and high-quality, globally accepted data. Under the Therapeutic Goods Administration’s (TGA) Clinical Trial Notification (CTN) scheme, many Phase I/II trials can begin significantly faster following ethics approval, without requiring a U.S. FDA Investigational New Drug (IND) application. This enables sponsors to generate first-in-human (FIH) data quickly and, in some cases, begin dosing in Australia while U.S. IND preparation continues. Costs are often estimated to be 30–40% lower than in the U.S., and Australia’s R&D Tax Incentive can provide refundable rebates of up to 43.5% of eligible expenditures for smaller companies. The FDA and EMA routinely accept the data. While operational challenges such as geographic distance, cross-border logistics, and regulatory harmonization require proactive management, early planning and experienced local partners make them readily manageable.
Read our white paper to learn more about:
- How Australia’s streamlined CTN regulatory pathway accelerates study start-up and enables first patient in within two to three months
- The cost advantages of conducting Phase I trials in Australia, including lower operational costs, favorable exchange rates, and R&D Tax Incentives that can reduce overall trial costs
- Why Australia’s ICH-GCP-compliant data, robust IP protections, and role as a gateway to Asia-Pacific clinical development make it an ideal launchpad for global programs
